{"filings":[{"id":100778,"accession_number":"0001140361-26-004822","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Strata Skin Sciences to be delisted from Nasdaq on Feb 19 after failing equity requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company failed to meet Nasdaq's minimum $2.5M stockholders' equity; funding efforts unsuccessful.","Nasdaq suspension of trading effective Feb 19, 2026; company will not appeal.","Plans to file Form 25 to delist and Form 15 to terminate SEC registration and 'go dark'.","Expects cost savings from reduced reporting obligations, enabling focus on operations and cash burn.","Stockholders face increased illiquidity; may sell shares before suspension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117080,"accession_number":"0001140361-25-045846","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin posts investor presentation; no material financial updates revealed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted Dec 16, 2025 on corporate website (gcs-web.com).","Presentation titled 'Driving Value in Therapeutic and Aesthetic Dermatology'; no new financial data or guidance included.","No specific product, revenue, or strategic milestones disclosed in the limited exhibit available.","Filing under Regulation FD; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117079,"accession_number":"0001140361-25-045145","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Strata Skin Sciences annual meeting elects all five directors; incentive plan amendment approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Dr. Uri Geiger, Dr. Irit Yaniv, Christina Allgeier, Shmuel Rubinstein, Dr. Dolev Rafaeli.","Shareholders approved amendment to 2016 Omnibus Incentive Plan, increasing reserved shares by 520,000.","Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2025 approved.","Votes for directors ranged from 2.18M to 2.23M; broker non-votes of 1.01M on director and plan items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117078,"accession_number":"0001140361-25-041985","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q3 revenue $6.9M (-21% YoY); net loss narrows to $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.9M (-21% YoY); net loss $1.6M (EPS -$0.36) vs $2.1M loss (EPS -$0.51) last year.","Global recurring revenue $5.5M (+3% YoY); equipment revenue $1.4M (-60%).","EBITDA slightly positive vs -$0.2M; cash $7.1M after $2.4M registered direct offering.","CMS recognized expanded CPT codes for XTRAC; COFEPRIS cleared TheraClearX in Mexico.","XTRAC install base 838 (-6); TheraClearX 161; avg gross billings per device $5,981 (+8.5%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":21404000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117077,"accession_number":"0001213900-25-099578","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Strata Skin Sciences files prospectus supplement for up to $11M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registers up to $11.0M in common stock for sale at-the-market under existing S-3 registration statement.","Prospectus supplement dated September 26, 2025 filed with SEC; Ladenburg Thalmann acts as sales agent.","No actual sales or pricing disclosed; shares offered from time to time under equity distribution agreement.","Opinion of Stevens & Lee, P.C. on legality of shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117076,"accession_number":"0001213900-25-098755","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Strata Skin Sciences gains Nasdaq extension to Feb. 16, 2026 for equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq accepted Strata's plan and extended the deadline to Feb. 16, 2026 to meet the $2.5M stockholders' equity requirement.","Company originally received a deficiency notice on Aug. 22, 2025 and submitted a compliance plan on Sept. 19, 2025.","Strata is evaluating options to regain compliance, but cautions there is no guarantee of success; non-compliance by the deadline could lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133528,"accession_number":"0001140361-25-034000","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences closes $2.42M registered direct offering of 1.1M shares at $2.204","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 1,097,547 shares at $2.204 per share.","Gross proceeds of approximately $2.42 million; Ladenburg Thalmann acted as placement agent.","Net proceeds to be used for working capital and general corporate purposes.","Offering was made under effective shelf registration statement (File No. 333-283418).","Closing occurred on September 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133527,"accession_number":"0001213900-25-083709","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences prices $2.42M registered direct offering at $2.204/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.","Gross proceeds expected ~$2.42M; net proceeds for working capital and general corporate purposes.","Ladenburg Thalmann acting as sole placement agent with 7.0% cash fee plus up to $50,000 expense reimbursement.","Closing expected on or about September 4, 2025, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133526,"accession_number":"0001140361-25-032373","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Strata Skin Sciences receives Nasdaq deficiency notice for equity below $2.5M; must submit plan by October 3, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Strata on Aug 19, 2025 of non-compliance with minimum stockholders' equity requirement of $2.5M.","Company reported equity below requirement in Q2 10-Q and does not meet alternative compliance standards.","Company has until Oct 3, 2025 to submit a plan to regain compliance; if accepted, Nasdaq may grant up to 180-day extension.","Failure to regain compliance could lead to delisting; company is evaluating options.","Stock continues trading under SSKN on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133525,"accession_number":"0001140361-25-031629","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences posts investor presentation on its website on August 18, 2025","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Strata Skin Sciences (NASDAQ: SSKN) posted an investor presentation to its website on August 18, 2025.","The presentation is attached as Exhibit 99.1 to the current Form 8-K filed with the SEC.","The company's presentation is available at https://strataskinsciencesinc.gcs-web.com/.","The disclosure is furnished under Item 7.01 and not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133524,"accession_number":"0001140361-25-030853","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q2 revenue down 9% to $7.7M; net loss widens to $2.5M, EPS -$0.60","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.7M (down 9% YoY); net loss $2.5M vs $0.1M loss in Q2 2024 (EPS -$0.60 vs -$0.03).","Gross profit $4.3M (56% of revenue) vs $5.0M in prior year.","Cash at June 30 $6.0M; nearly operating cash flow breakeven when adjusted for $1.3M NY tax payment and ~$340k legal costs.","CPT code expansion triples covered patient population; G-code application filed for accelerated 2026 reimbursement.","Removed 21 XTRAC devices, placed 19 (highest in six quarters); lawsuit against LaserOptek adds defendants."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":14475000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133523,"accession_number":"0001140361-25-029355","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata seeks CMS temporary codes for expanded XTRAC reimbursement; triples addressable market to 30M+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Working with CMS to secure temporary codes for expanded CPT codes for XTRAC, aiming for 2026 reimbursement instead of 2027.","Expanded coding triples addressable patient population to over 30M for inflammatory and autoimmune skin conditions.","Two new studies show excimer laser plus JAK inhibitors safe and effective for vitiligo, supporting XTRAC use.","Federal court adds LaserOptek Korea and C. Dalton as defendants in false advertising lawsuit; STRATA encouraged by ruling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150201,"accession_number":"0001140361-25-019786","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AMA expands CPT codes for SSKN's XTRAC laser; now covers vitiligo, atopic dermatitis, alopecia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AMA CPT Editorial Panel revised codes 96920-96922 to include inflammatory/autoimmune skin diseases beyond psoriasis.","Expanded coverage unlocks up to 30M potential patients (vs. 10M psoriasis-only), including 3M vitiligo, 16.5M atopic dermatitis patients.","Expected to reduce systemic denials and prior authorizations; non-psoriasis treatments were ~30% of 2023 Medicare volume.","CEO Dr. Rafaeli calls it an 'inflection point' for XTRAC; company expects accelerated revenue growth and broader clinic adoption.","STRATA collaborated with leading dermatologists (Dr. Lebwohl, Dr. Grimes, Dr. Richard) on the CPT change application."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150200,"accession_number":"0001140361-25-019005","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q1 2025 revenue $6.8M up 1%; net loss narrows to $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.8M (+1% YoY); gross margin expanded 790 bps to 53.5%.","Net loss $2.4M (EPS -$0.58) vs $3.4M loss (-$0.96) in Q1 2024.","Adjusted EBITDA improved to -$0.55M from -$1.3M; operating expenses fell 5% to $5.7M.","International revenue grew 8% YoY, now 36% of total; DTC drove 32% more psoriasis patients.","Cash at quarter-end $7.8M; operating cash flow improved to -$0.55M."],"consensus_eps_estimate":-0.5263,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6812000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150199,"accession_number":"0001140361-25-015780","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Strata Skin Sciences replaces auditor: Marcum resigns, CBIZ engaged","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 23, 2025; CBIZ CPAs P.C. engaged same day with Audit Committee approval.","No disagreements with Marcum on accounting principles or financial statement disclosure during FY2024/2023 or through resignation.","Prior material weakness in internal controls (lack of detailed management review) was reported; no other reportable events.","Marcum's audit reports for FY2024 and FY2023 were unqualified and not modified as to uncertainty or scope.","Marcum's resignation followed CBIZ's acquisition of Marcum's attest business on November 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169210,"accession_number":"0001140361-25-010713","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Q4 rev +10% to $9.6M; net loss $4.5M; adj. EBITDA improves to $2.2M in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $9.6M, up 10% from $8.7M; net loss $4.5M (EPS -$1.18 vs -$1.09).","Full-year 2024 revenue $33.6M (flat); net loss $10.1M (EPS -$2.65).","Gross margin improved to 60.1% in Q4 (480 bps YoY); non-GAAP adj. EBITDA $2.2M vs $1.0M.","Domestic XTRAC units reduced to 864; avg rev per device up 6% to $5,906.","International Q4 sales $4.1M (+41% YoY); cash $8.6M at year end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169209,"accession_number":"0001140361-25-009587","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences highlights clinical study showing excimer laser superiority over excimer light","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Published study from Nippon Medical School shows excimer laser penetrates deeper into hair follicles and activates more melanocyte stem cells than excimer light.","Laser delivers 1,000 mJ/cm² in one second vs 20 seconds for excimer light, with less DNA damage and epidermal side effects.","Over 100 XTRAC excimer lasers placed in Japan since 2019, including 24 in 2024; global installed base exceeds 2,800 units.","CEO states study validates XTRAC's technological advantages for treating vitiligo, psoriasis, alopecia areata, and atopic dermatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186249,"accession_number":"0001140361-24-048963","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences posts investor presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor presentation posted to company website on December 11, 2024.","Presentation titled 'Driving Value in Dermatology' with tagline 'Matching Patients with Clinics'.","No specific financial results, guidance changes, or material events disclosed in filing.","Filing is for Regulation FD purposes; presentation is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186248,"accession_number":"0001140361-24-046508","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q3 rev $8.8M, first non-GAAP operating profit since 2018","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $8.8M (-1% YoY); recurring revenue $5.4M (+2% YoY); gross margin 60.3% (up from 56.0% YoY).","Non-GAAP operating profit $128K (excl. $1.8M NY tax accrual); first since 2018 refinancing.","Net loss narrowed to $0.3M ($0.08/sh) from $1.1M ($0.30/sh) in Q3 2023; cash $8.4M.","XTRAC domestic base 873 (down from 882 Q2); TheraClear X base 135 (up from 117 Q2).","Designated John Gillings (VP Finance) as principal financial & accounting officer; raised $2.1M in July equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":23986000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186247,"accession_number":"0001140361-24-045945","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences wins court order barring LaserOptek from false marketing of Pallas lasers","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for Eastern PA issued order in STRATA's favor against LaserOptek, Monarch Laser Services, and Pinnacle Health Group.","Order enjoins LaserOptek and Pinnacle from marketing Pallas lasers as reimbursable under CPT codes 96920-96922.","Also bars any false/misleading statements about Pallas lasers or STRATA's lasers in U.S. sales and promotion.","Court order is a partial conclusion of STRATA's preliminary injunction motion; STRATA continues pursuing monetary and equitable relief.","CEO Dolev Rafaeli states defendants' behavior caused significant monetary and reputational damages to STRATA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186246,"accession_number":"0001140361-24-044583","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Strata Skin Sciences shareholders re-elect all five directors and ratify Marcum LLP as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Dr. Uri Geiger, Dr. Irit Yaniv, Christina Allgeier, Shmuel Rubinstein, Dr. Dolev Rafaeli.","Ratification of Marcum LLP as independent registered public accounting firm for FY 2024 approved with 3,166,313 votes for, 53,201 against.","No other business proposals were presented or approved beyond the stated agenda."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202875,"accession_number":"0001140361-24-038470","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences sues LaserOptek, MLS, Pinnacle for false advertising of Pallas lasers","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed complaint in U.S. District Court for Eastern District of Pennsylvania alleging unfair competition and false advertising under Lanham Act.","Claims defendants misrepresented that Pallas lasers qualify for CMS reimbursement codes reserved for excimer lasers like STRATA's XTRAC.","Also alleges false statements of technological and clinical equivalence without scientific evidence, causing harm to competition and patients.","Seeks injunctive relief, actual and treble damages, disgorgement of profits, and legal costs from LaserOptek, MLS, and Pinnacle.","Defendants include Korean manufacturer LaserOptek (KOSDAQ), its U.S. distributor Monarch Laser Services, and advisor Pinnacle Health Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202874,"accession_number":"0001140361-24-037322","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Q2 net loss narrows to $0.1M; revenue +2% to $8.4M; gross margin 58.5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.1M ($0.03 per share) vs $3.1M loss in prior year; operating loss cut to $0.5M from $2.0M.","Revenue $8.4M (+2% YoY); global recurring revenue $5.3M (-2% YoY) due to deferred billings; equipment revenue $3.1M.","Gross margin 58.5% vs 52.3% YoY; operating expenses $5.4M (-14% YoY).","XTRAC domestic base down to 882 from 907 at March; TheraClear X base up to 117 from 104.","Raised $2.1M in July offering; received Japan approval for XTRAC Momentum 1.0; renewed China/Japan distributor pacts."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":15189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202873,"accession_number":"0001140361-24-033878","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Closes $2.1M Direct Offering with Insider Participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 665,136 shares at $3.16/share for gross proceeds of $2.1 million.","Insiders and existing shareholders participated in the registered direct offering.","CEO Dolev Rafaeli said insider participation shows conviction in strategic plan and path to profitability.","Proceeds will extend the company's cash runway to support turnaround and growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202872,"accession_number":"0001140361-24-033358","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences announces clinical study showing TheraClear X reduces acne lesions by ≥50% after three treatments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Study in Journal of Cosmetic and Laser Therapy (July 11, 2024) evaluated 7 female patients with mild-moderate acne.","All patients achieved ≥50% clearance of comedones, pustules, and inflammatory lesions after three treatments.","Side effects were mild and transient: erythema, bruising, superficial erosions, temporary pigmentation changes (48-72 hours).","TheraClear X is FDA-cleared as a noninvasive, in-office treatment for mild-to-moderate acne, combining vacuum and broadband light.","President and CEO Dr. Dolev Rafaeli cited photopneumatic therapy as a viable alternative for patients resistant to traditional treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202871,"accession_number":"0001140361-24-032885","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"STRATA pre-announces Q2 revenue $8.0M-$8.4M; XTRAC base down, TheraClear X up","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary Q2 2024 total revenue range: $8.0M - $8.4M.","Domestic XTRAC installed base fell from 907 (Q1) to 881 (Q2) per device realignment.","TheraClear X installed base grew from 104 (Q1) to 117 (Q2).","Cash, cash equivalents, and restricted cash totaled $6.8M at quarter end.","Full Q2 2024 results expected to be reported on August 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":15189000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219069,"accession_number":"0001140361-24-031327","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"STRATA Skin Sciences regains Nasdaq compliance, avoids delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on June 24, 2024 that it now satisfies continued listing requirements under Rule 5550(a)(2).","Company will continue to trade on Nasdaq under ticker SSKN.","No additional details on prior deficiency or remedial actions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219068,"accession_number":"0001140361-24-028814","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Strata Skin Sciences announces 1-for-10 reverse stock split effective June 6, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio of 1-for-10 approved by board on April 26, 2024, effective 11:59 p.m. June 6.","Post-split common stock begins trading on Nasdaq Capital Market on June 7, 2024, under same symbol SSKN.","New CUSIP number 86272A 305; no fractional shares issued, cash paid in lieu.","Stockholders' percentage interest unchanged; outstanding equity awards proportionally adjusted.","Stockholders pre-approved the reverse split range (1:5 to 1:25) at special meeting on October 26, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219067,"accession_number":"0001140361-24-026254","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"STRATA Skin Sciences Q1 revenue $6.8M (-11% YoY); net loss widens to $3.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.8M vs $7.6M YoY; global recurring revenue $4.7M (-10% YoY).","Net loss $3.4M ($0.10 per share) vs $2.8M ($0.08) in Q1 2023.","Gross margin fell to 46% from 58% YoY; operating expenses cut 14% to $6.0M.","Domestic installed base: 907 XTRAC (down from 923 in Dec 2023); 104 TheraClear X (up from 92).","Amended credit agreement with MidCap Financial; renewed 3-year exclusive distributor deals in China and Japan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":6754000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219066,"accession_number":"0001140361-24-022571","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences announces 1-for-10 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-10 effective 11:59 p.m. ET June 6, 2024; trading begins June 7 under same symbol SSKN with new CUSIP 86272A 305.","Split aimed at meeting Nasdaq's $1.00 minimum bid price requirement for continued listing.","Shareholders approved a reverse split range (1-for-5 to 1-for-25) on October 26, 2023; announcement satisfies deadline to specify ratio by April 26, 2024.","No fractional shares issued; holders of fractional shares will receive cash based on pre-split closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238953,"accession_number":"0001140361-24-015650","cik":1051514,"company_name":"STRATA Skin Sciences, Inc.","ticker":"SSKN","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.","Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.","Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.","Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.","Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":824347.7685950415,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}